ANI Pharmaceuticals Inc. has released a corporate presentation outlining its financial performance and growth projections. The company highlights its focus on rare diseases and generics as key drivers of robust and profitable growth. ANI Pharmaceuticals reports a significant portion of its revenue, approximately 95%, is derived from products sold in the U.S., with over 90% of these products manufactured domestically. The presentation also emphasizes the importance of adjusted non-GAAP EBITDA and diluted earnings per share as indicators of operating performance, unaffected by non-cash stock-based compensation and other financial variables. You can access the full presentation through the link below.